Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Edegem – page 25

509 clinical trials in Edegem, Belgium across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Edegem at a glance
509
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

509 trials in Edegem

Open in trial search

Triple negative breast cancer

Not recruiting

Study of Datopotamab Deruxtecan with or without Durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Influenza

Not recruiting

Study of mRNA-based seasonal influenza vaccine combinations compared to standard influenza vaccines in adults aged 18 and older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:GSKVX000000034794
  • Sponsor:GlaxoSmithKline Biologicals

Multifocal motor neuropathy

Not recruiting

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Small cell lung cancer

Not recruiting

Study of Tarlatamab Treatment in Patients with Small Cell Lung Cancer: Evaluation of Different Dosing Schedules

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Influenza immunisation

Not recruiting

Study on the Safety and Immune Response of a High-Dose Influenza Vaccine in Adults Aged 60 and Over, Comparing Trivalent Influenza Vaccine with a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238)
  • Sponsor:Abbott Biologicals B.V.

Influenza

Not recruiting

Study on the Effectiveness and Safety of CR9114 for Preventing Influenza in Healthy Adults

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:WILD-TYPE A INFLUENZA VIRUS A/BELGIUM/4217/2015 (H3N2)
  • Sponsor:Leyden Laboratories B.V.

Epileptic encephalopathy

Not recruiting

Title: Study of LP352 (bexicaserin) oral solution versus placebo for treating seizures in children and adults with Developmental and Epileptic Encephalopathies

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Longboard Pharmaceuticals Inc.

COVID-19

Not recruiting

Study on the Immune Response to Bretovameran COVID-19 mRNA Vaccine in Healthy Adults Aged 18-40

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:University Of Antwerp

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine Alone and with COVID-19 mRNA Vaccine in Adults Aged 50 and Above

Not recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Raxtozinameran
  • Sponsor:GlaxoSmithKline Biologicals

Pneumococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal Polysaccharide Serotype 1
  • Sponsor:Sanofi Vaccines US Inc.

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Edegem

What the registry says about research in the country

01 Infectious Diseases & Immunology

Groundbreaking research focusing on viral infections and vaccine development, including studies for influenza, RSV, and COVID-19. Multiple trials are evaluating immune responses and vaccine efficacy in different age groups.

  • Vaccine Development
  • Immune Response Studies
  • Prevention Strategies

Special attention is given to vulnerable populations, including elderly adults and pregnant women.

02 Liver & Metabolic Disorders

Innovative studies addressing Primary Biliary Cholangitis and Hepatitis D treatments. Research includes evaluation of novel therapeutics and their impact on disease progression.

  • Liver Disease Management
  • Clinical Outcomes
  • Antiviral Therapies

Trials focus on improving patient outcomes and developing targeted treatments.

03 Oncology & Cancer Care

Advanced research in breast cancer and lung cancer treatments, exploring new therapeutic combinations and targeted approaches for better patient outcomes.

  • Metastatic Disease
  • Targeted Therapies
  • Treatment Innovation

Focus on personalized medicine approaches and innovative treatment combinations.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.